Abbott Cancerguard Advances Multi-Cancer Detection Data

ABBOTT PARK, Ill., April 17, 2026

Abbott has unveiled new data at the AACR Annual Meeting 2026 demonstrating significant advancements in its Cancerguard® multi-cancer early detection (MCED) test, highlighting the power of a multi-biomarker approach to detect cancers at earlier stages. The findings reinforce the potential of blood-based diagnostic technologies to transform cancer screening by enabling earlier intervention and improved patient outcomes, particularly for cancers that currently lack routine screening options.

Multi-Biomarker Strategy Enhances Early Detection Accuracy

The latest data show that combining methylation and protein biomarkers significantly improves the ability to detect cancer across multiple stages and tumor types. The Cancerguard® test, designed as a first-of-its-kind multi-biomarker MCED platform, demonstrated that 47.1% of detected cancer signals were driven by methylation alone, while 7.4% were identified through protein biomarkers, and 45.5% through combined signals, highlighting the complementary role of each biomarker class.

Importantly, the study revealed that early-stage cancers are often detected through a single biomarker class, emphasizing the importance of integrating multiple biological signals to achieve broader and more sensitive detection. The test also demonstrated high specificity, with only 2.6% false-positive results, none of which were positive across both biomarker types, indicating strong reliability in clinical settings.

This approach addresses a major limitation in traditional screening methods, where reliance on a single biomarker may miss early-stage disease. By leveraging multi-dimensional biological data, Cancerguard aims to provide more comprehensive and accurate cancer detection.

DETECT-A Study Validates Long-Term Clinical Impact

In addition to new data, the AACR Cancer Prevention Research Award recognized the landmark DETECT-A study, which provides long-term evidence supporting the clinical value of multi-cancer early detection testing. The study, involving more than 10,000 participants, demonstrated that patients diagnosed with stage I or II cancers remained alive and cancer-free after a median follow-up of approximately four years, highlighting the life-saving potential of early detection.

The DETECT-A trial was the first large-scale prospective interventional study to evaluate a blood-based MCED test in a real-world setting, combining liquid biopsy technology with standard-of-care screening. The findings underscore the potential of MCED to detect cancers before symptoms appear, significantly improving treatment outcomes.

Given that nearly 70% of cancers occur in types without recommended screening, these results highlight the critical need for innovative diagnostic tools capable of identifying cancers earlier and more effectively.

Transforming Cancer Screening with Blood-Based Diagnostics

The Cancerguard® test is a laboratory-developed test (LDT) designed to detect multiple cancers from a simple blood draw, offering a minimally invasive alternative to traditional diagnostic methods. It integrates multi-biomarker analysis with imaging-based diagnostic pathways, helping reduce unnecessary follow-up procedures while maintaining high diagnostic accuracy.

By enabling early-stage detection of aggressive cancers, including those without existing screening protocols, Cancerguard represents a major step forward in precision diagnostics and preventive oncology. However, it is important to note that the test has not yet received FDA clearance, and ongoing research will continue to evaluate its clinical utility and regulatory pathway.

Abbott’s advancements reflect a broader shift toward integrated diagnostic solutions, combining biomarker science, data analytics, and clinical validation to improve healthcare outcomes. As the field of liquid biopsy and MCED technologies continues to evolve, such innovations are expected to play a central role in the future of cancer care.

The latest AACR 2026 data position Abbott’s Cancerguard® test as a promising advancement in multi-cancer early detection, leveraging a multi-biomarker approach to improve accuracy, sensitivity, and clinical impact. With strong supporting evidence from the DETECT-A study and ongoing innovation in diagnostic technology, Abbott is advancing the future of early cancer detection and precision medicine, with the potential to significantly improve survival outcomes worldwide.

Source: Abbott press release